Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 16
2015 5
2016 20
2017 11
2018 8
2019 4
2020 8
2021 3
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Assessment of afoxolaner efficacy against Otodectes cynotis infestations of dogs.
Carithers D, Crawford J, de Vos C, Lotriet A, Fourie J. Carithers D, et al. Parasit Vectors. 2016 Dec 9;9(1):635. doi: 10.1186/s13071-016-1924-4. Parasit Vectors. 2016. PMID: 27938395 Free PMC article.

BACKGROUND: The efficacy of a single 2.5 mg/kg dose of afoxolaner (NexGard, Merial) against induced Otodectes cynotis infestations was assessed in eight afoxolaner-treated dogs, compared to eight untreated dogs. ...Significantly fewer (P < 0.05) live mites were p

BACKGROUND: The efficacy of a single 2.5 mg/kg dose of afoxolaner (NexGard, Merial) against induced Otodectes cynotis infestations wa …
Safety evaluation of orally administered afoxolaner in 8-week-old dogs.
Drag M, Saik J, Harriman J, Larsen D. Drag M, et al. Vet Parasitol. 2014 Apr 2;201(3-4):198-203. doi: 10.1016/j.vetpar.2014.02.022. Epub 2014 Mar 13. Vet Parasitol. 2014. PMID: 24629431 Free article.
The study ended at Day 126. The groups were: Group 1: non-treated control; Group 2: afoxolaner chews administered at a dosage of at least 6.3mg/kg (1); Group 3: afoxolaner chews administered at a dosage of at least 18.9 mg/kg (3); and Group 4: afoxolaner chew …
The study ended at Day 126. The groups were: Group 1: non-treated control; Group 2: afoxolaner chews administered at a dosage of at l …
Discovery and mode of action of afoxolaner, a new isoxazoline parasiticide for dogs.
Shoop WL, Hartline EJ, Gould BR, Waddell ME, McDowell RG, Kinney JB, Lahm GP, Long JK, Xu M, Wagerle T, Jones GS, Dietrich RF, Cordova D, Schroeder ME, Rhoades DF, Benner EA, Confalone PN. Shoop WL, et al. Vet Parasitol. 2014 Apr 2;201(3-4):179-89. doi: 10.1016/j.vetpar.2014.02.020. Epub 2014 Mar 14. Vet Parasitol. 2014. PMID: 24631502 Free article.
Afoxolaner has comparable potency between wild type channels and channels possessing the A302S (resistance-to-dieldrin) mutation. Lack of cyclodiene cross-resistance for afoxolaner was confirmed in comparative Drosophila toxicity studies, and it is concluded that
Afoxolaner has comparable potency between wild type channels and channels possessing the A302S (resistance-to-dieldrin) mutation. Lac
The intravenous and oral pharmacokinetics of afoxolaner used as a monthly chewable antiparasitic for dogs.
Letendre L, Huang R, Kvaternick V, Harriman J, Drag M, Soll M. Letendre L, et al. Vet Parasitol. 2014 Apr 2;201(3-4):190-7. doi: 10.1016/j.vetpar.2014.02.021. Epub 2014 Mar 29. Vet Parasitol. 2014. PMID: 24685320 Free article.
Afoxolaner is a member of one of the newest classes of antiparasitic agents, known as antiparasitic isoxazolines. ...When afoxolaner is administered orally, there is a strong correlation between afoxolaner plasma concentration and efficacy with EC90 values of
Afoxolaner is a member of one of the newest classes of antiparasitic agents, known as antiparasitic isoxazolines. ...When afoxolan
The intravenous and oral pharmacokinetics of afoxolaner and milbemycin oxime when used as a combination chewable parasiticide for dogs.
Letendre L, Harriman J, Drag M, Mullins A, Malinski T, Rehbein S. Letendre L, et al. J Vet Pharmacol Ther. 2017 Jan;40(1):35-43. doi: 10.1111/jvp.12332. Epub 2016 Sep 7. J Vet Pharmacol Ther. 2017. PMID: 27604405
Absorption of actives was rapid at levels that provide the minimum effective doses of 2.5 mg/kg and 0.5 mg/kg of afoxolaner and milbemycin oxime, respectively. The time to maximum afoxolaner plasma concentrations (t(max) ) was 2-4 h. ...The pharmacokinetic profile f …
Absorption of actives was rapid at levels that provide the minimum effective doses of 2.5 mg/kg and 0.5 mg/kg of afoxolaner and milbe …
Safety evaluation of orally administered afoxolaner and milbemycin oxime in eight-week-old dogs.
Drag M, Saik J, Harriman J, Letendre L, Yoon S, Larsen D. Drag M, et al. J Vet Pharmacol Ther. 2017 Oct;40(5):447-453. doi: 10.1111/jvp.12375. Epub 2016 Nov 27. J Vet Pharmacol Ther. 2017. PMID: 27891622 Clinical Trial.
Treatment groups were as follows: Group 1: untreated, sham-dosed control; Group 2: afoxolaner/milbemycin oxime chews administered at a dose of at least 5 and 1 mg/kg, respectively (1); Group 3: afoxolaner/milbemycin oxime chews administered at a dose of at least 15 …
Treatment groups were as follows: Group 1: untreated, sham-dosed control; Group 2: afoxolaner/milbemycin oxime chews administered at …
Efficacy of oral afoxolaner for the treatment of canine generalised demodicosis.
Beugnet F, Halos L, Larsen D, de Vos C. Beugnet F, et al. Parasite. 2016;23:14. doi: 10.1051/parasite/2016014. Epub 2016 Mar 24. Parasite. 2016. PMID: 27012161 Free PMC article. Clinical Trial.
Afoxolaner was administered at the recommended dose (at least 2.5 mg/kg) on Days 0, 14, 28 and 56. ...Skin condition of the dogs also improved significantly from Day 28 to Day 84 in the afoxolaner-treated group. Mite reductions were significantly higher on Days 28,
Afoxolaner was administered at the recommended dose (at least 2.5 mg/kg) on Days 0, 14, 28 and 56. ...Skin condition of the dogs also
Efficacy of afoxolaner in the flea control in experimentally infested cats.
Machado MA, Campos DR, Lopes NL, Bastos IPB, Alves MSR, Correia TR, Scott FB, Fernandes JI. Machado MA, et al. Rev Bras Parasitol Vet. 2019 Oct-Dec;28(4):760-763. doi: 10.1590/S1984-29612019064. Rev Bras Parasitol Vet. 2019. PMID: 31483035 Free article.
The aim of this study was to evaluate the efficacy of a single dose of oral afoxolaner in controlling fleas in cats. Fourteen cats were used. The cats were given identification numbers, housed individually, artificially infested with Ctenocephalides felis felis, and treate …
The aim of this study was to evaluate the efficacy of a single dose of oral afoxolaner in controlling fleas in cats. Fourteen cats we …
Effect of oral afoxolaner on naturally occurring infestations of peacocks by the louse Goniodes pavonis.
Yarto Jaramillo E, Osorio Marquez R, Rangel Díaz J, Romero Núñez C, Miranda Contreras L, Heredia Cardenas R. Yarto Jaramillo E, et al. Vet Dermatol. 2019 Apr;30(2):167-e50. doi: 10.1111/vde.12713. Epub 2018 Dec 17. Vet Dermatol. 2019. PMID: 30556631
The haematocrit improved in the afoxolaner-treated group from a baseline of 46.4%-54.7% at 35 days post-treatment, whereas it decreased in untreated birds (44.6%-40.7%). No adverse effects attributed to afoxolaner treatment were observed. CONCLUSIONS AND CLINICAL IM …
The haematocrit improved in the afoxolaner-treated group from a baseline of 46.4%-54.7% at 35 days post-treatment, whereas it decreas …
74 results